A61P 7 - Drugs for disorders of the blood or the extracellular fluid

Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065)
11/2009
11/17/2009	CA2249181C Scf analog compositions and methods
11/12/2009	WO2009135888A2 Complex
11/12/2009	WO2009135433A1 Use of total salvianolic acid, panax notoginsenosides and combination thereof in treating septicemia
11/12/2009	WO2009135432A1 The use of salvianolic acid b on anti- thrombus
11/12/2009	WO2009135352A1 A plum tree extract, a method for preparing the plum tree extract and use thereof
11/12/2009	WO2009071691A3 Oxindole derivatives and the use thereof as a medication
11/12/2009	US20090281139 Macrocyclic factor viia inhibitors useful as anticoagulants
11/12/2009	US20090281128 Caspase inhibitors and uses thereof
11/12/2009	US20090281086 2 -oxyheteroarylamide derivatives as parp inhibitors
11/12/2009	US20090281059 Coating for a medical device having an anti-thrombotic conjugate
11/12/2009	US20090281040 Methods For Treating Endoplasmic Reticulum (ER) Stress Disorders
11/12/2009	US20090281027 Modified vitamin k-dependent polypeptides
11/12/2009	US20090280117 Methods for the treatment or prevention of immune disorders using anti-cd40 antibodies
11/12/2009	US20090280085 Long Acting Human Interferon Analogs
11/12/2009	CA2723746A1 Complex
11/11/2009	EP2116237A1 Compositions for treating rosacea comprising chitosan and a dicarboxylic acid
11/11/2009	EP2114944A2 Tetrahydrobiopterin prodrugs
11/11/2009	EP2114922A1 Substituted oxindole derivative and its use as a vasopressin receptor modulator
11/11/2009	EP2114434A1 Method for inducing thrombopoiesis
11/11/2009	EP1669462B1 Method of preparing alpha-glycosylisoquercitrin, intermediate therefor and by-product
11/11/2009	EP1668002B1 2,4-dioxo-3-quinazolinylaryl sulfonylureas
11/11/2009	EP1557407B1 Novel alpha-ketoamide derivatives and use thereof
11/11/2009	EP1495762B1 Therapeutic lotion for dermatitis
11/11/2009	EP1397351B1 Pyrimidine, triazine and pyrazine derivatives as glutamate receptors
11/11/2009	EP1339673B1 Malonamide and malonamic ester derivatives with antithrombotic activity, their preparation and their use
11/11/2009	EP1181048B1 A pharmaceutical formulation containing an inhibitor of carboxypeptidase u and a thrombin inhibitor
11/11/2009	CN101574520A Methods of administering anti-TNF alpha antibodies
11/11/2009	CN101574511A Traditional Chinese medicine composition for curing purpura
11/11/2009	CN101574474A Traditional Chinese medicine composition for curing purpura
11/11/2009	CN101574469A Traditional Chinese medicine for treating passionate type swine plague
11/11/2009	CN101574467A Traditional Chinese medicine preparation for curing purpura
11/11/2009	CN101574463A Method for controlling quality of Fuke Zhixueling capsule
11/11/2009	CN101574454A Restoration traditional Chinese medicine
11/11/2009	CN101574440A Traditional Chinese medicine for treating thrombocytopenic purpura
11/11/2009	CN101574421A Medicament for treating leukemia and septicemia
11/11/2009	CN101574378A Chinese medicament for treating woman uterine bleeding
11/11/2009	CN101574336A Di-(4-chlorobenzoyl hydroximic acid) di-n-butyl tin and applications of salts thereof in preparing medicaments with the function of increasing leucocytes
11/11/2009	CN100558895C The anti-platelet membrane glycoprotein VI monoclonal antibody
11/11/2009	CN100558744C Use of a recombinant erythropoietin having high activity and reduced side effects
11/11/2009	CN100558712C Therapeutic molecules and methods-1
11/11/2009	CN100558371C Application of Chinese medicine composition in treating cardiac and cerebral vascular diseases
11/11/2009	CN100558346C Chinese medicinal preparation for statis moving hemostatis, swell dispersing pain stopping and its preparation method
11/11/2009	CN100558344C Solid formulation for dialysis and process for producing the same
11/10/2009	US7615622 Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor VIII
11/10/2009	US7615573 Via amino ceramide-like compounds; lowering glycosphingolipid concentrations; Fabry's disease, Gaucher's disease
11/10/2009	US7615219 Treatment of decreased blood platelet numbers by neutralizing anti-PACAP antibody or antigen-binding fragment; haemostasis
11/10/2009	CA2481482C Tropane derivatives as ccr5 modulators
11/10/2009	CA2421410C Iron compositions
11/10/2009	CA2410862C Factor viia inhibitory (thio)urea derivatives, their preparation and their use
11/10/2009	CA2401637C N-(heterocyclyl)benzene- or - pyridinesulphonamides as antithrombotic and anticoagulant agents
11/10/2009	CA2371213C Inhibitors of carboxypeptidase u
11/10/2009	CA2299421C A universally applicable blood plasma
11/05/2009	WO2009134754A1 Benzoimidazole glycinamides as prolyl hydroxylase inhibitors
11/05/2009	WO2009134750A1 Benzoimidazoles as prolyl hydroxylase inhibitors
11/05/2009	WO2009134383A2 Vinyl substituted fatty acids
11/05/2009	WO2009134130A2 Treatment of bleeding with low half-life fibrinogen
11/05/2009	WO2009133278A1 Porous crystalline hybrid solid for adsorbing and releasing gas of biological interest
11/05/2009	WO2009132575A1 Nattokinase powders with super high activity and producing method thereof
11/05/2009	WO2009105164A3 Blood substitute solution
11/05/2009	US20090275576 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino[4,5-b]indole-1-carboxamide derivatives, their preparation and therapeutic use
11/05/2009	US20090274774 Citrate-Based Dialysate Chemical Formulations
11/05/2009	US20090274737 Implant comprising a surface of reduced thrombogenicity
11/05/2009	US20090274680 Human Phospholipases
11/05/2009	US20090274671 Vector encoding human globin gene and use thereof in treatment of hemoglobinopathies
11/05/2009	CA2729053A1 Vinyl substituted fatty acids
11/05/2009	CA2722772A1 Benzoimidazoles as prolyl hydroxylase inhibitors
11/05/2009	CA2720008A1 Porous crystalline hybrid solid for adsorbing and releasing gas of biological interest
11/04/2009	EP1432700B1 Spiro-hydantoin compounds useful as anti-inflammatory agents
11/04/2009	EP1311488B1 Substituted imidazoles as tafia inhibitors
11/04/2009	CN101573354A Substituted isoquinolines and their use as Rho-kinase inhibitors
11/03/2009	US7612238 Such as (R)-2-amino-2-methyl-4-[4-(4,4,5,5,5-pentafluoro-pentyloxy)-phenyl]-butan-1-ol hydrochloride for treatment of disorders or diseases mediated by lymphocytes, and for treating acute or chronic transplant rejection or T-cell-mediated inflammatory or autoimmune diseases
11/03/2009	US7612110 Immunosuppressants; for use in transplantation medicine or treatment of autoimmune diseases such as polyarthritis but not psoriatitc arthritis; micro-tablets, pellets
11/03/2009	US7612109 Water-soluble iron-carbohydrate complexes, production thereof, and medicaments containing said complexes
11/03/2009	US7612083 Urea substituted imidazoquinoline ethers
11/03/2009	US7612075 Anticaogulants; cardiovascular disorders
11/03/2009	US7612066 1-(3-tert-butyl-4-methoxy-5-morpholinophenyl)-2-(5,6-diethoxy-7-fluoro-1-imino-1,3-dihydroisoindol-2-yl)ethanone,; stabilizing the composition; not decompose even when placed under humidification conditions
11/03/2009	US7612047 Degradation-resistant mononucleoside phosphate compounds
11/03/2009	US7612033 administering to the cell a composition which comprises the compound to be delivered and an organic halide such as a perfluorocarbon; ultrasound
11/03/2009	US7611729 Dosage forms having prolonged active ingredient release
11/03/2009	US7611707 Glycoprotein VI antibodies and methods thereof
11/03/2009	CA2383220C Controlled release pellet formulation
11/03/2009	CA2205379C Yeast-based delivery vehicles
11/03/2009	CA2181548C Zinc finger protein derivatives and methods therefor
10/2009
10/29/2009	WO2009131201A1 Therapeutic agent for intermittent claudication
10/29/2009	WO2009131129A1 5-hydroxypyrimidine-4-carboxamide compound
10/29/2009	WO2009131127A1 5-hydroxypyrimidine-4-carboxamide compound
10/29/2009	WO2009130289A1 HYDROGENSULFATE SALT OF 2-ACETOXY-5-(a-CYCLOPROPYLCARBONYL-2-FLUOROBENZYL)-4,5,6,7-TETRAHYDROTHIENO[3,2-c]PYRIDINE AND ITS PREPARATION
10/29/2009	WO2009129983A1 Acid addition salts of prasugrel and pharmaceutical compositions comprising the same
10/29/2009	WO2009129945A1 Substituted dihydropyrazolones as inhibitors of hif-prolyl-4-hydroxylases
10/29/2009	WO2009129913A1 Solid pharmaceutical preparation comprising 1-[(4-chloro-phenyl)-amide]-2-{[4-(3-oxo-morpholine-4-yl)-phenyl]-amide}-4-hydroxy-pyrrolidine-1,2-dicarboxylic acid
10/29/2009	WO2009043355A3 SYSTEMIC PRO-HEMOSTATIC EFFECT OF SYMPATHICOMIMETICS WITH AGONISTIC EFFECTS ON α-ADRENERGIC AND/OR β-ADRENERGIC RECEPTORS OF THE SYMPATHETIC NERVOUS SYSTEM, RELATED TO IMPROVED CLOT STRENGTH
10/29/2009	US20090270498 Lipoxin Compounds and Their use in Treating Cell Proliferative Disorders
10/29/2009	US20090270456 Novel chemical compounds
10/29/2009	US20090270446 Diamine derivatives
10/29/2009	US20090270332 Genetic polymorphisms associated with venous thrombosis, methods of detection and uses thereof
10/29/2009	US20090270329 Methods of administering porcine b-domainless fviii
10/29/2009	US20090270328 Methods of increasing cerebral blood flow
10/29/2009	US20090269325 using non-anticoagulant sulfated polysaccharides (NASPs) e.g. pentosan polysulfate or heparins as procoagulants for treating bleeding disorder selected from a chronic or acute bleeding disorder, a congenital coagulation disorder caused by a blood factor deficiency, and an acquired coagulation disorder
10/29/2009	US20090269283 Method and product for locating an internal bleeding site
10/29/2009	DE102008020053A1 Feste pharmazeutische Zubereitung enthaltend A solid pharmaceutical preparation containing 1-[(4-chloro-phenyl)-amid]-2-{[4-(3-oxo-morpholin-4-yl)-phenyl]-amid}-4-hydroxy-pyrrolidin-1,2-dicarbonsäure

1 ... 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 ... 671